ModernMedicine Resource Center More Topics

Hot Topics in Prostate Cancer

SBRT yields excellent Ca control, low rate of severe toxicityResults from a multicenter study show progression-free survival in 97% of low- and intermediate-risk prostate cancer patients.
Researchers ID markers of resistance to two PCa therapiesFindings from a recent study indicate that CTCs detected in blood have the potential to reveal important genetic information that could guide treatment selection.
Test predicts PCSM at 10 years post prostatectomyNew research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.
HIFU results in low morbidity, QoL preservationAnother study suggests that hemiablation with high-intensity focused ultrasound is a promising treatment for unilateral localized prostate cancer.
How cutting carbs may benefit men on hormonal therapyRecent data show that a low-carbohydrate diet may have significant positive effects in men on hormonal therapy for prostate cancer, including metabolic effects. In this interview, study author Stephen J. Freedland, MD, discusses his group’s findings, ongoing research on diet and lifestyle changes in men with prostate cancer, and how he counsels patients.
Prostate Ca phenotypic assay predicts adverse clinical pathologyIn this interview, Dr. David Albala sits down to discuss his award-winning poster on live-cell phenotypic biomarkers at the 2016 AUA with Urology Times Editorial Consultant, Dr. J. Brantley Thrasher.
Are you seeing more advanced prostate Ca in your practice?Three urologists give their take on the frequency of patients presenting with prostate cancer.
The return of prostate cancer: A step backwardUrologist Henry Rosevear, MD discusses his thoughts on PSA screening and the recent increase in patients presenting with metastatic disease.
Early-stage PCa incidence drops post-USPSTFThe authors of a recent research letter reported a 6% drop in incidence rates for early-stage prostate cancer in men 50 years of age and older from 2012 to 2013.
What influences opting out of active surveillance?A recent study suggests that a man’s race/ethnicity might influence decisions about undergoing treatment and re-biopsies.